Genentech
Genentech is a US-based biotechnology subsidiary of Roche Holding AG that develops and commercializes biologic and small-molecule medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic disease, serving patients, hospitals, and specialty pharmacies worldwide.
- Company typePrivate
- Founded1976
- HeadquartersSouth San Francisco, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Genentech does
Genentech, Inc. is a US-based biotechnology research and biopharmaceutical company founded in 1976 in South San Francisco, California. It operates as a wholly-owned subsidiary of Roche Holding AG following Roche's 2009 acquisition for approximately $46.8 billion, serving as the primary US-based research, development, and commercialization vehicle for the Roche Group. The company develops, manufactures, and commercializes a broad portfolio of biologic and small-molecule medicines across five therapeutic areas: oncology (Tecentriq, Vabysmo, Hemlibra, Herceptin, Avastin, Polivy, Lunsumio, Columvi, Venclexta, Itovebi, Kadcyla, Perjeta, Phesgo, Rozlytrek, Alecensa, Zelboraf), immunology (Actemra, Rituxan, Gazyva, Xolair), neuroscience (Ocrevus, Enspryng, Evrysdi), ophthalmology (Vabysmo, Susvimo, Lucentis, Luxturna), and emerging areas including metabolic disease and obesity (enicepatide, petrelintide in Phase III). It maintains additional franchises in hematology (PiaSky) and infectious disease (Xofluza, Tamiflu).
Genentech's underlying technology combines established biologics manufacturing with AI/ML-augmented drug discovery. The Prescient Design platform provides machine learning-based protein design; a partnership with Recursion Pharmaceuticals extends AI-driven discovery into the clinic; and Roche's Galileo platform supports enterprise agentic AI for scientific discovery. Novel drug delivery technology includes the FDA-approved Port Delivery System (Susvimo), a refillable reservoir for continuous ranibizumab delivery in retinal disease, plus a growing set of subcutaneous reformulations (Phesgo, Ocrevus Zunovo, Tecentriq Hybreza, Rituxan Hycela, Lunsumio Velo) that improve convenience. Manufacturing scale is being expanded via a $700 million Holly Springs, North Carolina facility.
The business model centers on biopharmaceutical product sales through enterprise field sales, medical science liaisons, and specialty pharmacy distribution, complemented by Genentech Access Solutions for coverage support and the Genentech Patient Foundation, which provides free medicines to qualifying uninsured or underinsured patients. Revenue also includes co-commercialization economics, notably the joint U.S. commercialization of Venclexta with AbbVie. The company serves hospitals, oncology practices, neurology clinics, ophthalmology specialists, specialty pharmacies, and patients with serious and life-threatening diseases, with a 10,000+ employee base concentrated in South San Francisco and expanding US manufacturing operations.
Genentech firmographics
Firmographics- Name
- Genentech
- Legal name
- Genentech, Inc.
- Website
- https://gene.com
- Company type
- Private
- Founded year
- 1976
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Genentech is a US-based biotechnology subsidiary of Roche Holding AG that develops and commercializes biologic and small-molecule medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic disease, serving patients, hospitals, and specialty pharmacies worldwide.
- Ownership category
- akta.pro rank
Genentech industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services (HLAAACAM)
Keywords
Where Genentech is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Genentech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Genentech generates revenue through sales of its portfolio of approved biopharmaceutical medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic diseases. Products include Vabysmo, Tecentriq, Hemlibra, Ocrevus, Lucentis, Avastin, Herceptin, Rituxan, Actemra, Xolair, and others. Revenue flows through specialty pharmacies, hospital sales, and direct patient distribution channels.
- Co-commercialization Revenue: Venclexta (venetoclax) is jointly commercialized by AbbVie and Genentech in the U.S., representing a co-commercialization partnership revenue stream.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | TrumpRx discounted pricing for Xofluza |
| Other | Pay-as-you-go | Patient assistance programs |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Genentech product offering
Product offeringCore offering
Genentech develops, manufactures, and commercializes a broad portfolio of biopharmaceutical medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic diseases. Its products include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, gene therapies, and small molecule drugs such as Tecentriq, Herceptin, Avastin, Ocrevus, Vabysmo, Hemlibra, Venclexta, Polivy, and Susvimo. The company distributes these medicines through specialty pharmacies, hospital channels, and direct patient assistance programs, while also operating a patient foundation providing free medicines to uninsured individuals.
Product overview
Genentech's product portfolio is a diverse platform of biotechnology medicines spanning multiple therapeutic areas including oncology (Avastin, Herceptin, Tecentriq, Venclexta, Polivy, Lunsumio, Columvi, Alecensa, Kadcyla, Perjeta, Phesgo, Rozlytrek, Itovebi), immunology (Rituxan, Gazyva, Ocrevus, Xolair, Actemra), ophthalmology (Lucentis, Vabysmo, Susvimo), rare blood disorders (Hemlibra, PiaSky), neuroscience (Ocrevus, Enspryng), and infectious disease (Xofluza, Tamiflu). The portfolio includes both intravenous and subcutaneous formulations, with several products having received new indications or regulatory approvals recently, including expanded uses for Tecentriq in muscle-invasive bladder cancer and colon cancer, and Venclexta for chronic lymphocytic leukemia. The company also offers gene therapy (Luxturna) and has an advancing obesity portfolio including enicepatide and petrelintide in Phase III development. Genentech provides these medicines through patient support services including the Genentech Patient Foundation for those without insurance coverage.
Differentiator
Problem solved
Functional benefit
Brands
- Genentech Patient Foundation: A patient assistance program providing free Genentech medicines to people who don't have insurance coverage or who have financial concerns.
- Genentech Access Solutions
- MEDICALLY
Products and services
- Actemra (tocilizumab)
- Alecensa (alectinib)
- Avastin (bevacizumab)
- Columvi (glofitamab-gxbm)
- Enspryng (satralizumab-mwge)
- Evrysdi (risdiplam)
- Gazyva (obinutuzumab)
- Hemlibra (emicizumab-kxwh)
- Herceptin (trastuzumab)
- Itovebi (inavolisib)
- Kadcyla (ado-trastuzumab emtansine)
- Lucentis (ranibizumab injection)
- Lunsumio (mosunetuzumab-axgb)
- Luxturna (voretigene neparvovec-rzyl)
- Ocrevus (ocrelizumab)
- Perjeta (pertuzumab)
- Phesgo
- PiaSky (crovalimab-akkz)
- Polivy (polatuzumab vedotin-piiq)
- Rituxan (rituximab)
- Rozlytrek (entrectinib)
- Susvimo
- Tecentriq (atezolizumab)
- Vabysmo (faricimab-svoa)
- Venclexta (venetoclax)
- Xofluza (baloxavir marboxil)
- Xolair (omalizumab)
- Zelboraf (vemurafenib)
Quantifiable outcome
- 59% reduction in risk of disease progression or death with Lunsumio VELO + Polivy combination vs comparator in relapsed/refractory large B-cell lymphoma (Phase III SUNMO study)
- +3 more outcomes
Companies that use Genentech
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles2 records
Genentech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature5 records
Genentech partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- Prescient DesigncoreGenentech acquired Prescient Design to enhance antibody discovery capabilities through machine learning-based protein design. The acquisition was motivated by Prescient Design's unique platform and talented team, aiming to improve efficiency and effectiveness in identifying therapeutic antibodies.
- Sangamo TherapeuticscoreSangamo's proprietary STAC-BBB capsid has been licensed to Genentech for up to $4.6 billion in potential milestones. The capsid enables brain-targeting gene therapies.
- NateracoreFDA approved Signatera CDx as companion diagnostic for Tecentriq in muscle-invasive bladder cancer. First blood-based MRD companion diagnostic approved, identifying patients who may benefit from Tecentriq after cystectomy.
- Lineage Cell TherapeuticscoreWorldwide collaboration for OpRegen (RG6501) cell therapy for geographic atrophy secondary to age-related macular degeneration. Patients showed +9.0 ETDRS letters gain at 36 months with partial restoration of outer retinal structure.
- Recursion PharmaceuticalscoreAI-powered drug development partnership advancing clinical candidates including REC-1245 and REC-4881. Genentech continues as partnered program collaborator following Recursion's partnership with Sanofi.
- Caris Life SciencesminorDecember partnership with Genentech for molecular profiling services. Described as the largest pharma deal in Caris' history for precision oncology diagnostics.
- AbbViecoreCo-commercialization of Venclexta (venetoclax) in the U.S. Venetoclax is co-developed by AbbVie and Roche/Genentech, with positive Phase III CLL14 trial data showing 6.4-year median PFS.
- Lupus Research AlliancecoreCollaborative research program funding CAR-T cell therapy research for lupus. Inaugural recipients of Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus each receive $150,000 per year for up to two years.
- National Multiple Sclerosis SocietycoreFunding MS Care Desert Initiative in South Carolina - Genentech's largest corporate sponsorship to date for the Society's healthcare access programs. Part of three-state pilot including Wisconsin and Mississippi.
- Precede BiosciencesminorCollaboration at AACR 2026 for Precede Bio Insight liquid biopsy product enabling genome-wide inference of gene expression from 1mL plasma for predicting therapeutic response.
- BioNTechcoreCo-development of personalized mRNA cancer vaccine (autogene cevumeran) for pancreatic cancer. 87.5% of patients with strong T cell responses remain alive 4-6 years post-surgery vs median survival of 3.4 years for non-responders.
Scale indicators3 records
Recent moves7 records
Expansion highlights6 records
Genentech competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Genentech social profiles
Digital presenceGenentech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Genentech leadership team
Management profileNumber of profiles
Profiles5 records
Genentech funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Genentech M&A and investment
M&A and investmentM&A6 records
Investments17 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Genentech
What does Genentech do?
Genentech develops, manufactures, and commercializes a broad portfolio of biopharmaceutical medicines across oncology, immunology, neuroscience, ophthalmology, and metabolic diseases. Its products include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, gene therapies, and small molecule drugs such as Tecentriq, Herceptin, Avastin, Ocrevus, Vabysmo, Hemlibra, Venclexta, Polivy, and Susvimo. The company distributes these medicines through specialty pharmacies, hospital channels, and direct patient assistance programs, while also operating a patient foundation providing free medicines to uninsured individuals.
Is Genentech a public or private company?
Genentech is a private company. It is classified as corporate owned and is currently operating.
When was Genentech founded?
Genentech was founded in 1976. It employs 5,001 to 10,000 people.
Where is Genentech based?
Genentech is headquartered in South San Francisco, United States, in the North America region.
How does Genentech make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are co-commercialization Revenue.
Does Genentech have an API?
No public API is recorded for Genentech.
What industry is Genentech in?
Genentech's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.